CUL7

CUL7 Full Name

cullin 7

CUL7 Introduction

CUL7 (Cullin 7) is a large scaffold protein that belongs to the cullin family of E3 ubiquitin ligases and serves as a central component of the Cullin-RING ligase 7 (CRL7) complex. Encoded by the CUL7 gene on chromosome 6p21.1, CUL7 contains unique DOC and CPH domains that distinguish it from other cullin family members and enable specialized substrate recognition and regulatory interactions. Through assembly with RBX1, SKP1, and F-box proteins such as FBXW8 and FBXW11, CUL7 mediates the ubiquitination and subsequent degradation of key cellular proteins involved in growth control, cell cycle progression, and signal transduction. Because dysregulated protein turnover is a major challenge in cancer biology and developmental disorders, CUL7 has emerged as an important molecular target for understanding how cells maintain normal growth and tissue homeostasis. Its ability to interact with multiple signaling pathways places CUL7 at the crossroads of cellular proliferation, differentiation, and stress-response mechanisms.

From a functional perspective, CUL7 acts as both a protein degradation regulator and a broader signaling modulator. The CRL7 complex targets substrates such as IRS-1, Cyclin D1, and HPK1, thereby influencing insulin-like growth factor signaling, cell-cycle regulation, and apoptotic responses. In addition, CUL7 has been shown to interact with the tumor suppressor p53, attenuating p53-mediated transcriptional activity and affecting cell survival decisions under stress conditions. Emerging evidence indicates that CUL7 participates in epithelial-mesenchymal transition (EMT), cellular migration, and metastatic progression, highlighting its role in tissue remodeling and cancer dissemination. Beyond oncology, CUL7 is increasingly recognized as an important regulator of embryonic growth, placental development, cardiovascular maturation, and muscle development. Studies in animal models demonstrate that loss of CUL7 function disrupts normal vascular formation and fetal growth, underscoring its critical role in developmental biology and organogenesis.

The clinical significance of CUL7 spans both inherited genetic disorders and malignancies. Germline mutations in CUL7 are a well-established cause of 3-M syndrome, a rare autosomal recessive growth disorder characterized by severe pre- and postnatal growth retardation, skeletal abnormalities, and reduced stature. Pathogenic variants can impair CRL7 complex assembly, prevent proper substrate ubiquitination, and lead to abnormal accumulation of regulatory proteins involved in growth control. In cancer, elevated CUL7 expression has been reported in multiple tumor types, including breast cancer, lung cancer, hepatocellular carcinoma, pancreatic cancer, and ovarian cancer, where it is frequently associated with aggressive disease behavior, metastatic potential, and poor clinical outcomes. However, CUL7 appears to exhibit context-dependent biological functions, acting as either a tumor promoter or, in certain cellular environments, a tumor suppressor. This duality has attracted growing interest in the development of therapeutic strategies targeting the CRL7 pathway, including modulation of F-box proteins, inhibition of Cullin-RING ligase activity, and blockade of neddylation-dependent ubiquitin signaling. As research continues to uncover the diverse roles of CUL7 in growth regulation and disease progression, this protein is increasingly viewed as a promising biomarker and potential therapeutic target across oncology, developmental genetics, and regenerative medicine.

Alternate Names for CUL7

CUL7; cullin 7; 3M1; KIAA0076; dJ20C7.5; cullin-7; CUL-7;

• 1.Li Y, et al.; Cullin 7 in tumor development: a novel potential anti-cancer target. Neoplasma. 2021, 68(3):572-579.
  2.Shi L, et al.; The functional analysis of Cullin 7 E3 ubiquitin ligases in cancer. Oncogenesis. 2020, 9(10):98.